LCKLSL

LCKLSL is a N-terminal hexapeptide and a competitive annexin A2 (AnxA2) inhibitor. LCKLSL potently inhibits the binding of tissue plasminogen activator (tPA) to AnxA2. LCKLSL also inhibits the generation of plasmin and has anti-angiogenic roles[1].

Product Specifications

CAS Number

[533902-29-3]

UNSPSC

12352209

Target

Annexin A

Type

Peptides

Related Pathways

Cytoskeleton

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/lcklsl.html

Purity

98.00

Solubility

H2O : ≥ 50 mg/mL

Smiles

CC(C)C[C@@H](C(O)=O)NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC([C@H](CS)NC([C@H](CC(C)C)N)=O)=O)=O)=O)=O

Molecular Formula

C30H57N7O8S

Molecular Weight

675.88

References & Citations

[1]Mallika Valapala, et al. A Competitive Hexapeptide Inhibitor of Annexin A2 Prevents Hypoxia-Induced Angiogenic Events. J Cell Sci. 2011 May 1;124 (Pt 9) :1453-64.

Shipping Conditions

Blue Ice

Storage Conditions

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

Scientific Category

Peptides

Clinical Information

No Development Reported

Citation 01

Biomed Pharmacother. 2023 Mar:159:114173.|Inflamm Res. 2022 Sep;71 (9) :1067-1078.|iScience. 2025 Apr 2;28 (5) :112302.|J Immunother Cancer. 2025 Jun 26;13 (6) :e011716.|Biochem Pharmacol. 2025 Sep 6;242 (Pt 2) :117308.|Cell Commun Signal. 2024 Dec 21;22 (1) :616.|J Extracell Vesicles. 2024 Apr;13 (4) :e12425.|J Neurochem. 2022 Mar;160 (6) :662-674.